분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2012-12-22 17:22:12 , Hit : 2546
 Biopharma startup raises $51M for therapeutic to treat bleeding complications from angioplasty

December 19, 2012 6:41 pm by Stephanie Baum | 0 Comments


In one of the largest financing rounds this year, biopharmaceutical startup Regado Biosciences has raised $51 million to advance its anti-clotting therapeutic through Phase 3 clinical trials.

A subsidiary of Russian investment firm Rusnano,RusnanoMedInvest, led the Series E round. Baxter Ventures, part of Baxter Healthcare, also was a firsttime investor in the company., according to a company statement. Existing investors participating in the round included Edmond de Rothschild Investment Partners, Domain Associates, Quaker Partners, Aurora Funds and Caxton Advantage Life Sciences Fund also participated in the round.

Its lead treatment is REG 1, a therapeutic consisting of an aptamer paired with an active control agent. Aptamers, developed in vitro, have been likened to antibodies because of their binding affinity for their targets. The treatment’s lead indication is to control bleeding in coronary angioplasty procedures. The Basking Ridge, New Jersey biopharmaceutical startup is also pursuing a parallel indication for the therapeutic for use in open heart surgery.

Other treatment programs in its pipeline that will benefit from the new funding include its REG1 indication for transaortic valve implantation and its treatment for diabetic vasculopathy, a blood vessel disorder, expected to begin Phase 1 clinical trials in 2013.

The Phase 3 trial will look at the efficacy of the therapeutic. Patients will be enrolled at about 500 sites and it is expected to be completed two years after it begins.


Read more: http://medcitynews.com/2012/12/biopharma-startup-raises-51m-for-therapeutic-to-treat-bleeding-complications-from-angioplasty/#ixzz2Flc9jvPM







767   인간 게놈 백과사전 완성: 게놈은 유전자의 단순한 집합체가 아니다  이성욱 2012/09/10 2792
766   유전자 요법의 후각기능 회복  이성욱 2012/09/12 3160
765   “몸매는 날씬해야” 강박관념도 유전자 탓  이성욱 2012/10/04 2678
764   日 교토대, 쥐 유도만능줄기세포로 난자 만들어  이성욱 2012/10/06 3207
763   The Nobel Prize in Physiology or Medicine 2012  이성욱 2012/10/09 2577
762   Smallest and fastest-known RNA switches provide new drug targets  이성욱 2012/10/11 2492
761   Early-Earth cells modeled to show how first life forms might have packaged RNA  이성욱 2012/10/16 2587
760   유도만능줄기세포, 진짜 만능일까?  이성욱 2012/10/17 2722
759   Nobel work boosts drug development  이성욱 2012/10/23 2571
758   Whitehead scientists identify major flaw in standard approach to global gene expression analysis  이성욱 2012/10/29 2252
757   유럽 첫 유전자 치료제 승인 지단백 리파제 결핍약 '글리베라' 허가  이성욱 2012/11/06 3980
756   CU-Boulder researchers uncover new target for cancer research  이성욱 2012/11/06 2758
755   Genomics: The single life  이성욱 2012/11/06 2134
754   Glybera Gains Official EMA Nod as First Gene Therapy  이성욱 2012/11/06 2685
753   술 퍼먹게 하는 유전자 있다  이성욱 2012/12/07 2889
  Biopharma startup raises $51M for therapeutic to treat bleeding complications from angioplasty  이성욱 2012/12/22 2546
751   뇌의 신비 밝혀줄 지도가 만들어진다 - 올해는 휴먼 커넥톰 프로젝트가 완료되는 해  이성욱 2013/02/05 3534
750   Newly Identified Natural Protein Blocks HIV, Other Viruses  이성욱 2013/02/16 2288
749   'Activating' RNA takes DNA on a loop through time and space  이성욱 2013/02/19 2159
748   Electronics Giant Samsung Makes First Big Biotech Play  이성욱 2013/02/22 3205

[이전 10개] [1]..[21][22][23][24][25] 26 [27][28][29][30]..[64] [다음 10개]
 

Copyright 1999-2024 Zeroboard / skin by ROBIN